Obstetrics & Gynecology Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Obstetrics & Gynecology 1996;87:610-612
© 1996 by The American College of Obstetricians and Gynecologists
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Coulson, C.
Right arrow Articles by Cefalo, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Coulson, C.
Right arrow Articles by Cefalo, R.

Articles

Central hemodynamic effects of recombinant human relaxin in the isolated, perfused rat heart model

CC Coulson, Thorp JM Jr, DC Mayer, and RC Cefalo

OBJECTIVE: To determine the cardiac effects of relaxin in the isolated, perfused rat heart model, and to see if pregnancy modifies the hormone's actions. METHODS: Hearts were excised from 18 female Sprague-Dawley rats (ten pregnant, eight nonpregnant) and attached to a Langendorff apparatus. Left ventricular systolic pressure, heart rate, and contractility were measured. Hearts were exposed serially to 0.5, 1.0, 2.0, 4.0, 8.0, and 16.0 ng/mL concentrations of recombinant human relaxin. RESULTS: Hearts from pregnant rats had lower heart rates than those from nonpregnant animals. Relaxin increased heart rate, left ventricular systolic pressure, and contractility in a dose-dependent fashion. Pregnancy did not modify this response. CONCLUSION: Recombinant human relaxin is a potent inotropic and chronotropic agent. The effects coupled with the physiologic increase of relaxin during human pregnancy indicate that relaxin may be involved in the cardiovascular changes of pregnancy.


This article has been cited by other articles:


Home page
 Pharmacol. Rev.Home page
R. A. Bathgate, R. Ivell, B. M. Sanborn, O. D. Sherwood, and R. J. Summers
International Union of Pharmacology LVII: Recommendations for the Nomenclature of Receptors for Relaxin Family Peptides.
Pharmacol. Rev., March 1, 2006; 58(1): 7 - 31.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
D. O. Debrah, K. P. Conrad, A. Jeyabalan, L. A. Danielson, and S. G. Shroff
Relaxin Increases Cardiac Output and Reduces Systemic Arterial Load in Hypertensive Rats
Hypertension, October 1, 2005; 46(4): 745 - 750.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
K. P. Conrad and J. Novak
Emerging role of relaxin in renal and cardiovascular function
Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2004; 287(2): R250 - R261.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
O. D. Sherwood
Relaxin's Physiological Roles and Other Diverse Actions
Endocr. Rev., April 1, 2004; 25(2): 205 - 234.
[Abstract] [Full Text] [PDF]

Home page
 ANGIOLOGYHome page
N. J. Mehta, R. N. Mehta, and I. A. Khan
Peripartum Cardiomyopathy: Clinical and Therapeutic Aspects
Angiology, November 1, 2001; 52(11): 759 - 762.
[Abstract] [PDF]

Home page
 JAMAHome page
G. D. Pearson, J.-C. Veille, S. Rahimtoola, J. Hsia, C. M. Oakley, J. D. Hosenpud, A. Ansari, and K. L. Baughman
Peripartum Cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) Workshop Recommendations and Review
JAMA, March 1, 2000; 283(9): 1183 - 1188.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the American College of Obstetricians and Gynecologists.